ILB-202 / ILIAS Biologics - LARVOL DELTA

Safety and Anti-Inflammatory Effects of Engineered Extracellular Vesicles (ILB-202) for NF-κB Inhibition: A Double-Blind, Randomized, Placebo-Controlled Phase 1 Trial. (PubMed, J Extracell Vesicles) - P1 | "Single-cell RNA sequencing revealed subtle, time-dependent modulation of NF-κB-associated pathways, enhanced TGF-β and visfatin signalling and reduced TNF signalling-suggesting a shift towards an anti-inflammatory state. These findings support the safety and immunomodulatory activity of ILB-202 and pave the way for future trials in diseases characterized by dysregulated NF-κB activation. Trial Registration: ClinicalTrials.gov identifier: NCT05843799."

Clinical • Journal • P1 data • Hematological Disorders • Immunology • Inflammation • Neutropenia • NAMPT • NFKBIA • TGFB1

A Study to Evaluate the Safety and Tolerability of ILB-202 (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: ILIAS Biologics Inc. | Recruiting ➔ Completed

Trial completion

A Study to Evaluate the Safety and Tolerability of ILB-202 (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: ILIAS Biologics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Evaluate the Safety and Tolerability of ILB-202 (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: ILIAS Biologics Inc.

New P1 trial